Abaloparatide
|
Tymlos |
BA058|BA-058|BIM44058|BIM-44058 |
|
Abaloparatide (Tymlos) is a peptide analog of human parathyroid hormone-related protein (PTHrP), which stimulates bone formation and potentially increases bone mineral density (PMID: 25393645, PMID: 29260289). Abaloparatide (Tymlos) is FDA approved for osteoporosis (FDA.gov). |
Apalutamide
|
Erleada |
ARN-509|JNJ-56021927 |
Hormone - Anti-androgens
28
|
Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
Asparaginase Erwinia chrysanthemi
|
Erwinaze |
Crisantaspase |
|
Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov). |
Atezolizumab
|
Tecentriq |
RG7446|MPDL3280A |
Immune Checkpoint Inhibitor
98
PD-L1/PD-1 antibody
68
|
Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov). |
BCG solution
|
TICE BCG solution |
Bacillus Calmette-Guerin solution |
|
TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). |
Balsalazide
|
Carbadox |
Balsalazida |
|
Carbadox (balsalazide) is a 5-aminosalicylate (5-ASA) type drug that is FDA approved for the treatment of inflammation resulting from ulcerative colitis (FDA.gov), however, has also been demonstrated to induce apoptosis and decrease cell proliferation in cancer cells (PMID: 28108625). |
Brexucabtagene autoleucel
|
Tecartus |
KTE-X19 |
|
Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti CD-19 chimeric antigen receptor, which may potentially target CD-19 expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved fro use in adult patients with relapsed or refractory mantle cell lymphoma (FDA.gov). |
Capmatinib
|
Tabrecta |
INC280|INC-280|INCB028060|INCB28060|INCB 28060 |
MET Inhibitor
51
|
Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Carfilzomib
|
Kyprolis |
PR-171 |
|
Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells. Kyprolis (carfilzomib), in combination with lenalidomide and dexamethasone, is FDA approved for multiple myeloma (FDA.gov). |
Celecoxib
|
Celebra |
|
|
Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov) and also promotes apoptosis of tumor cells (PMID: 17909047). |
Cyclophosphamide
|
Cytoxan |
CPM |
Chemotherapy - Alkylating
14
|
Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Dacarbazine
|
Deticene |
Biocarbazine R |
Chemotherapy - Alkylating
14
|
Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle. Dacarbazine is FDA approved for melanoma (FDA.gov). |
Daratumumab
|
Darzalex |
JNJ-54767414 |
CD38 Antibody
7
|
Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov). |
Daratumumab and hyaluronidase-fihj
|
Darzalex Faspro |
Daratumumab/rHuPH20|HuMax-CD38-rHuPH20|darzalex/rHuPH20 |
|
Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is a combination of the anti-CD38 antibody Daratumumab with hyaluronidase, which may be administered subcutaneously (PMID: 32213342). Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, and in combination with bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light chain amyloidosis (FDA.gov). |
Darolutamide
|
Nubeqa |
BAY1841788|ODM-201 |
Hormone - Anti-androgens
28
|
Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer (FDA.gov). |
Daunorubicin
|
Cerubidine |
Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin |
Chemotherapy - Anthracycline
11
|
Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
Daunoxome
|
|
Liposomal daunorubicin citrate |
Chemotherapy - Anthracycline
11
|
Daunoxome is a liposomal formulation of the anthracyline, daunorubicin and is FDA approved for HIV-associated Kaposi’s sarcoma (FDA.gov). |
Decitabine and Cedazuridine
|
Inqovi |
ASTX-727|ASTX 727|ASTX727 |
Chemotherapy - Antimetabolite
12
|
Inqovi (decitabine and cedazuridine) is a combination of decitabine and cedazuridine, which may inhibit proliferation of tumor cells (PMID: 30926081). Inqovi (decitabine and cedazuridine) is an FDA approved chemotherapy agent (FDA.gov). |
Divalproex sodium
|
Depakote |
Valproate semisodium|Sodium divalproex |
HDAC Inhibitor
38
|
Depakote (Divalproex sodium) comprises a 1:1 mixture of valproic acid and sodium valproate, which acts as an HDAC inhibitor, potentially resulting in decreased growth and increased apoptosis of tumor cells in combination with other agents (PMID: 25449787, PMID: 20200483). Depakote (divalproex sodium) is FDA approved for treatment of manic episodes associated with bipolar disorder, as well as seizures, and migraines (FDA.gov). |
Doxorubicin
|
Adriamycin |
Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin |
Chemotherapy - Anthracycline
11
TOPO2 inhibitor
4
|
Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
Duvelisib
|
Copiktra |
IPI-145|INK1197 |
PIK3CD inhibitor
24
PIK3CG inhibitor
8
|
Copiktra (duvelisib) prevents the activation of the PI3K delta/gamma-mediated signaling pathways, resulting in tumor cell death (PMID: 25258342). Copiktra (duvelisib) is FDA approved for use in adult patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma (FDA.gov) |
Enfortumab vedotin-ejfv
|
Padcev |
AGS-22ME |
|
Padcev (enfortumab vedotin-ejfv) is an antibody drug conjugate that fuses together a human antibody against NECTIN4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). Padcev (enfortumab vedotin-ejfv) is FDA approved for use in patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy (FDA.gov). |
Entrectinib
|
Rozlytrek |
RXDX-101 |
ALK Inhibitor
23
ROS1 Inhibitor
14
Trk Receptor Inhibitor (Pan)
23
|
Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (12 years and older) patients with solid tumors harboring NRTRK fusions without known acquired resistance mutations (FDA.gov). |
Epirubicin
|
Ellence |
Epirubicin Hydrochloride |
Chemotherapy - Anthracycline
11
|
Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov). |
Fedratinib
|
Inrebic |
SAR302503|TG101348 |
FLT3 Inhibitor
55
JAK2 Inhibitor - ATP competitive
14
RET Inhibitor
39
|
Inrebic (fedratinib) binds and inhibits JAK2, FLT3, and RET kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402). Inrebic (fedratinib) is FDA approved for use in patients with myelofibrosis (FDA.gov). |
Fluorouracil
|
Adrucil |
5-FU |
Chemotherapy - Antimetabolite
12
|
Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
Fulvestrant
|
Faslodex |
ICI 182,780 |
Hormone - Anti-estrogens
18
|
Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Goserelin
|
Zoladex |
Goserelin acetate |
|
Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females, and is FDA approved for use in prostate carcinoma (FDA.gov). |
Ibritumomab tiuxetan
|
Zevalin |
IDEC Y2B8 |
CD20 Antibody
11
|
Zevalin (britumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (FDA.gov). |
Idarubicin
|
Idamycin |
Idarubicin Hcl |
Chemotherapy - Anthracycline
11
|
Idarubicin is an anthracycline, which inhibits DNA replication thereby preventing RNA and protein synthesis and, in combination with other approved drugs, is FDA approved for acute myelogenous leukemia (FDA.gov). |
Isatuximab
|
Sarclisa |
SAR650984|isatuximab-irfc |
CD38 Antibody
7
|
Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies (FDA.gov). |
KTE-C19
|
Yescarta |
KTE-C19 CAR|axicabtagene ciloleucel |
|
Yescarta (KTE-C19) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (Blood 2015 126:3991). Yescarta (KTE-C19) is FDA approved for treatment of relapsed or refractory large B-cell lymphoma (FDA.gov). |
Letrozole
|
Femara |
Letrozol |
Aromatase Inhibitor
3
|
Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
Lisocabtagene maraleucel
|
Breyanzi |
JCAR 017 |
|
Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (FDA.gov). |
Lorlatinib
|
Lorbrena |
PF-06463922 |
ALK Inhibitor
23
ROS1 Inhibitor
14
|
Lorbrena (lorlatinib) is a small molecule inhibitor of Alk and Ros1 fusion proteins, which may result in suppression of Alk and Ros1-mediated signaling thereby inhibiting cell growth and causing tumor regression (PMID: 26144315). Lorbrena (lorlatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov). |
Lurbinectedin
|
Zepzelca |
PM01183 |
|
Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
Margetuximab-cmkb
|
Margenza |
MGAH22|MGAH-22 |
HER2 (ERBB2) Antibody
50
|
Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov). |
Melphalan
|
Alkeran |
|
Chemotherapy - Alkylating
14
|
Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov). |
Methotrexate
|
Abitrexate |
Amethopterin |
Chemotherapy - Antimetabolite
12
|
Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). |
Mitomycin gel
|
Jelmyto |
UGN-101|Mitogel|MP77-08 |
|
Jelmyto (mitomycin gel) is a prolonged release gel formulation of mitomycin that may have antitumor activity when applied in the upper urinary tract (PMID: 32670424). Jelmyto (mitomycin for pyelocalyceal solution) is FDA approved for use in patients with low-grade upper tract urothelial cancer (FDA.gov). |
Naxitamab
|
Danyelza |
hu3F8 |
|
Danyelza (naxitamab) is an antibody that targets the ganglioside GD2, potentially resulting in increased anti-tumor immune response against GD2-expressing tumor cells (PMID: 22754766). Danyelza (naxitamab) is FDA approved for use in combination with GM-CSF in pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who achieved a partial response, minor response, or stable disease to prior therapy (FDA.gov). |
Omacetaxine mepesuccinate
|
Synribo |
homoharringtonine|CGX-635 |
|
Synribo (omacetaxine mepesuccinate) is a semisynthetic alkaloid that inhibits protein synthesis, resulting in increased apoptosis and cell-cycle arrest in tumor cells (PMID: 26935769, PMID: 24516334). Synribo (omacetaxine mepesuccinate) is FDA approved for use in patients with chronic myeloid leukemia (FDA.gov). |
Orlistat
|
Xenical |
(-)-Tetrahydrolipstatin |
|
Xenical (orlistat) is a fatty acid inhibitor that also demonstrates anti-tumor activity (PMID: 30667213). Xenical (orlistat) is FDA approved for weight management (FDA.gov). |
Oxaliplatin
|
Eloxatin |
Diaminocyclohexane Oxalatoplatinum |
Chemotherapy - Platinum
6
|
Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
Pegylated liposomal-doxorubicin
|
Doxil |
ATI-0918|CAELYX |
Chemotherapy - Anthracycline
11
|
Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
Pexidartinib
|
Turalio |
PLX3397|CML-261 |
CSF1R Inhibitor
25
FLT3 Inhibitor
55
KIT Inhibitor
51
|
Turalio (pexidartinib) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190). Turalio (pexidartinib) is FDA approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
Pomalidomide
|
Pomalyst |
CC-4047 |
|
Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
Pralsetinib
|
Gavreto |
BLU667|BLU-667 |
RET Inhibitor
39
|
Gavreto (pralsetinib) is a small molecule inhibitor that selectively targets activated Ret, which may result in antitumor activity including inhibition of tumor growth and tumor regression (PMID: 29657135). Gavreto (pralsetinib) is FDA approved for use in patients with metastatic MET fusion-positive non-small cell lung cancer, in adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer, and in adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who are radioactive iodine-refractory (FDA.gov). |
Ripretinib
|
Qinlock |
DCC-2618|DCC2618 |
KIT Inhibitor
51
PDGFR-alpha Inhibitor
9
|
Qinlock (ripretinib) is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183, PMID: 31085175, PMID: 31201392). Qinlock (ripretinib) is FDA approved for use in patients with advanced gastrointestinal stromal tumor who received 3 or more prior kinase inhibitor therapies (FDA.gov) |
Sacituzumab govitecan-hziy
|
Trodelvy |
IMMU-132|Sactizumab |
|
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more priotr therapies (FDA.gov). |
Siltuximab
|
Sylvant |
CNTO 328|CNTO328 |
|
Sylvant (siltuxmab) is an anti-IL-6 chimeric monoclonal antibody, which inhibits IL6 signaling and may lead to decreased tumor cell growth (PMID: 26170629, PMID: 26744529). Sylvant (siltuximab) is FDA approved for patients with multicentric Castleman's disease who do not have HIV or HHV-8 (FDA.gov). |
Sulindac
|
Clinoril |
MK-231 |
|
Clinoril (sulindac) is a non-selective COX1-2 inhibitor, FDA approved as an anti-inflammatory agent (FDA.gov), and Clinoril (sulindac) also reduces intestinal tumor burden (PMID: 19755659). |
Tafasitamab-cxix
|
Monjuvi |
MOR00208|XmAb5574|MOR-208|MOR208 |
CD19 Antibody
10
|
Monjuvi (tafasitamab-cxix) is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329, PMID: 32511983). Monjuvi (tafasitamab-cxix) is FDA approved for use in combination with Revlimid (lenalidomide) in patients with relapsed or refractory diffuse large B cell lymphoma (FDA.gov). |
Tepotinib
|
Tepmetko |
EMD1214063|EMD-1214063EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J |
MET Inhibitor
51
|
Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Thalidomide
|
Thalomid |
N-Phthalimidoglutamic acid imide |
|
Thalomid (thalidomide) is a a racaemic glutamic acid analogue that has anti-inflammatory, anti-angiogenic, immunosuppressive, and anti-tumor activities (PMID: 15172781). Thalomid (thalidomide) is approved for use in combination with dexamethasone for patients with newly diagnosed multiple myeloma (FDA.gov). |
Tocilizumab
|
Actemra |
Atlizumab |
|
Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Tofacitinib
|
Xeljanz |
Tasocitinib|CP-690550|CP-690,550 |
JAK Inhibitor (Pan) - ATP competitive
3
|
Xeljanz (tofacitinib) is a pan-JAK inhibitor, which decreases downstream signaling and potentially leads to reduced tumor cell growth (PMID: 26300391, PMID: 21106989). Xeljanz (tofacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
Trastuzumab deruxtecan
|
Enhertu |
DS-8201|DS8201a|T-DXd|DS-8201a|fam-trastuzumab deruxtecan-nxki |
HER2 (ERBB2) Antibody
50
|
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, and in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based therapy (FDA.gov). |
Tretinoin
|
|
Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA |
|
Tretinoin is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Tretinoin is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
Umbralisib
|
Ukoniq |
RP5264|TGR-1202 |
PIK3CD inhibitor
24
|
Ukoniq (umbralisib) is a selective inhibitor of PIK3CD, which prevents Akt phosphorylation and induces cytotoxicity (J Clin Oncol 32:5s, 2014 (suppl; abstr 2513), PMID: 30709431). Ukoniq (umbralisib) is FDA approved for use in adult patients with relapsed or refractory marginal zone lymphoma with one or more prior anti-CD20-based therapy, and in adult patients with relapsed or refractory follicular lymphoma who have three or more prior lines of therapy (FDA.gov). |
Vincristine sulfate liposome
|
Marqibo |
VSL |
|
Marqibo (vincristine sulfate liposome) is a liposomal formulation of vincristine with improved bioavailability (PMID: 23212117). Marqibo (vincristine sulfate liposome) is FDA-approved for Philadelphia chromosome (BCR-ABL1)-negative acute lymphoblastic leukemia (FDA.gov). |
Vinorelbine
|
Navelbine |
Vinorelbin |
Antimicrotubule Agent
12
|
Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
Vorinostat
|
Zolinza |
SAHA|L-001079038|MSK390 |
HDAC Inhibitor
38
|
Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov). |
Zanubrutinib
|
Brukinsa |
BGB-3111 |
BTK inhibitor
24
|
Brukinsa (zanubrutinib) inhibits Bruton tyrosine kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing cells (PMID: 31378456). Brukinsa (zanubrutinib) is FDA approved for use in patients with mantle cell lymphoma (FDA.gov). |